Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.49 |
| ▸ | CA1 | P00915 | 6/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | ESRRB | O95718 | 1/20 | 0.39 |
| ▸ | ESRRG | P62508 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14431419 | 0.88 | CA2 (0.52) | CA2CA1NAMPTNQO2MAPT | |
| SCHEMBL30679781 | 0.86 | HDAC1 (0.48) | CA2CA1NAMPTHDAC1 | |
| SCHEMBL2948305 | 0.86 | HDAC1 (0.48) | CA2CA1NAMPTHDAC1 | |
| SCHEMBL30679783 | 0.86 | HDAC1 (0.48) | CA2CA1NAMPTHDAC1 | |
| SCHEMBL4451726 | 0.85 | MAPT (0.51) | CA2CA1NAMPTNQO2MAPT | |
| SCHEMBL6685945 | 0.85 | CA2 (0.50) | CA2CA1NAMPTNQO2MAPT | |
| SCHEMBL6680633 | 0.84 | CA2 (0.49) | CA2CA1NAMPTNQO2MAPT | |
| SCHEMBL6677541 | 0.84 | CA2 (0.49) | CA2CA1NAMPTNQO2MAPT | |
| SCHEMBL6678480 | 0.83 | CA1 (0.50) | CA2CA1NAMPTMAPTLMNA | |
| SCHEMBL16415452 | 0.83 | CA2 (0.46) | CA2CA1NAMPTNQO2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | CA2 3312/4885CA1 3029/4885NAMPT 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.